Anna Bratulic is a journalist with a focus on the pharmaceutical and biotech industries. She covers a wide range of topics, including drug development, clinical trials, regulatory updates, and business news. Anna has a keen interest in providing accurate and up-to-date information to readers in the healthcare and life sciences sectors.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Anna's coverage primarily focuses on the healthcare and pharmaceutical industry, particularly drug development, clinical trials, and FDA approvals. Her articles heavily feature press releases and cited data.
Given Anna’s focus on private sector announcements and reliance on data, she is likely to be responsive to pitches offering insights from professionals within the pharmaceutical industry who can provide in-depth analysis of new drugs or treatments. Pitches should highlight concrete data or exclusive details related to drug development processes, clinical trial results, or regulatory approvals.
While no specific geographic focus is mentioned for Anna's reporting, her topics cover international pharmaceutical developments rather than a localized perspective.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Industry veterans Nathaniel "Ned" David and Norman "Ned" Sharpless on Tuesday unveiled a new biotech venture foundry – Jupiter Bioventures – armed
Valora Therapeutics has emerged as the new kid on the block in immunotherapy, securing $30 million in seed funding to develop a different approach
Sage Therapeutics has definitively ended development of dalzanemdor, its experimental cognitive impairment drug, after the compound failed to
NewAmsterdam Pharma's experimental once-daily cholesterol treatment took another step forward Wednesday with positive Phase III TANDEM study
Novartis is betting on direct cellular engineering through a collaboration with Vyriad, the companies announced Wednesday.
By: Anna Bratulic
Versant Ventures is adding another weight loss startup to its roster of portfolio companies, launching Pep2Tango Therapeutics with a multi-receptor approach to treating obesity.
HOOKIPA Pharma is implementing a dramatic restructuring plan that will shrink its workforce by about 80% and pause clinical development of its human
AstraZeneca's bid to convert its anticoagulant reversal drug Andexxa (andexanet alfa) from accelerated to full approval faces headwinds after an
Having recently secured an FDA nod for Tremfya in ulcerative colitis with an intravenous induction regimen, Johnson & Johnson has now filed to gain
Halozyme Therapeutics has pulled its €2-billion ($2.1 billion) acquisition proposal for Evotec after multiple failed attempts to engage the German
(833) 317-6278 